Ypsomed (YPSN) investor relations material

Strategic transformation and business focus

• Transitioned to a pure-play injection device specialist by divesting non-core and diabetes care businesses between 2022 and 2025.

• Portfolio centers on pens, autoinjectors, and on-body devices, with a strong emphasis on digital and eco-friendly innovations.

• Offers the widest range of self-injection solutions, supporting over 70 approved therapies across multiple therapeutic areas.

• No customer accounts for more than 15% of sales, ensuring low concentration risk and a diversified client base.

• Closely monitors the evolving pharma ecosystem for future opportunities and bundled services.

Market trends and growth drivers

• Shift of therapies from hospital to home and the rise of injectables over orals are fueling demand.

• Biosimilars and obesity treatments (notably GLP-1/incretins) are significant growth areas, with GLP/incretins expected to reach 30% of sales by decade's end.

• Autoimmune and chronic disease therapies drive high-volume device demand.

• Project revenue from clinical customization provides midterm visibility into future commercial sales.

Product innovation and global expansion

• Launched three new device platforms in 2025, including the award-winning YpsoLoop autoinjector and eco-friendly, circular economy-ready designs.

• Expanded product launches in Asia, including first-in-class incretin and Alzheimer therapies.

• Global production footprint expanding, with new sites in Switzerland, Germany, China, and a U.S. facility in North Carolina set for completion by 2027.

• Celebrated milestones: Schwerin II topping-out in Germany (2025), Changzhou site opening in China (2025), and US expansion in Holly Springs (opening 2027).

• Production capacity targeted at 1 billion devices by early next decade, aligned with customer demand.